Actively Recruiting
Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia
Led by Pia Wintermark · Updated on 2025-01-14
60
Participants Needed
2
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Around the time of birth, some babies experience a condition called asphyxia, which means that their brain and other organs do not receive enough blood and/or oxygen to work properly. This life-threatening condition accounts for nearly 1 out of 4 deaths of all babies around the world, and often leads to severe brain damage, cerebral palsy, epilepsy, and trouble with learning and functioning in everyday life. At this time, no treatment is available to repair the brain damage caused by asphyxia. Excitingly, a drug called sildenafil (Viagra®) is already given safely to babies who suffer from increased blood pressure in their lungs' vessels. Recent studies using a laboratory model of asphyxia at birth suggest that sildenafil may also repair the brain damage caused by asphyxia. Similarly, recent small studies have shown that it is both feasible and safe to give sildenafil to human babies, who suffered from asphyxia at birth. These studies also highlight the first promising signs that sildenafil may improve how the brains of these babies work, which is consistent with the abovementioned laboratory studies. On the basis of these previous researches, the investigators predict that sildenafil can repair the damage to a baby's brain. The investigators will test whether sildenafil can be safely given to a large group of human babies who suffer from asphyxia at birth, and will confirm whether sildenafil improves or not how their brains and hearts/lungs work. This project will enable to determine whether sildenafil is a promising treatment for repairing brain damage in babies who suffer from asphyxia at birth. This project may also provide new solutions for these babies to improve their future life.
CONDITIONS
Official Title
Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female newborns meeting criteria for induced hypothermia
- Gestational age 36 weeks or more
- Birth weight 1800 grams or more
- Evidence of fetal distress such as acute perinatal event, cord pH 7.0 or lower, or base deficit 16 mEq/L or more
- Evidence of neonatal distress including Apgar score 5 or less at 10 minutes, blood gas pH 7.0 or lower within first hour, or need for ventilation for at least 10 minutes
- Moderate to severe neonatal encephalopathy by abnormal neurological exam or brain monitoring (aEEG)
- Undergoing whole-body cooling to 33.56C within first 6 hours of life for 72 hours followed by rewarming
- Brain injury confirmed by MRI on day 2 of life
You will not qualify if you...
- Newborns with complex congenital heart disease
- Newborns with brain malformations
- Newborns with genetic syndromes
- Newborns with brain hemorrhage on day 2 MRI
- Babies who are moribund and not expected to survive
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Montreal Children's Hospital
Montreal, Quebec, Canada, H3C 0T3
Actively Recruiting
2
Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, Canada, H3T 1C5
Actively Recruiting
Research Team
P
Pia Wintermark, MD
CONTACT
G
Gabriel Altit, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here